Cliniche Gavazzeni S.p.A. — Clinical Trial Site

48 Registered trials

20 Currently recruiting

Organisation

Cliniche Gavazzeni S.p.A.

Location

Bergamo, Italy

Identifier

ORG-100043623

Address

Via Mauro Gavazzeni 21, 24125, Italy

Departments

4116: U.O.C. di Urologia
Cardiologia
Cardiology
Cardiovascular Department
Centro Oculistico
Dipartimento di Oncologia
Humanitas Gavazzeni
Humanitas Gavazzeni - U.O. Oncologia Medica – Unità di Oncologia Toracica
Interventional Cardiologist
Medical oncology
Oncologia
Oncologia Medica
Oncology Cliniche Gavazzeni S.p.A.
Oncology Department
Radiotherapy
Reparto di oncologia
Thoracic and Urologic Oncology Unit
U.O. Oncologia Medica
Unità di Oncoematologia
Unità Oncologia Medica
Unità Operativa di Urologia
UO di Urologia
UO Oncologia Medica
Urologia
Urology

Clinical trials at this site (48)

Search interface

Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial) Pending

2024-518388-37-00 Intermediate risk prostate cancer 4
Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA T… Pending

2024-520093-34-00 Acinar cell prostatic carcinoma 5
Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Pending

2025-523947-36-00 Sub-study 5: Unresectable Pleural Mesothelioma (Volrust 4
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the… Recruiting

2024-511239-91-00 Resectable Stage I-III Non-Small Cell Lung Cancer (NSCL 4 2025-05-05
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic… Recruiting

2024-512423-36-00 Undifferentiated pleomorphic sarcoma 5 2024-11-20
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting

2024-519493-39-00 High-risk Non-muscle-invasive Bladder Cancer with Susce 5 2025-12-09
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Metastatic Castration-Resistant Prostate Cancer 5 2025-06-23
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting

2023-507641-29-00 Locally Advanced or Metastatic Solid Tumors 4 2024-07-15
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie… Recruiting

2023-506662-31-00 Gastric or gastroesophageal cancer 4 2024-02-28
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting

2023-503206-37-00 Mantle Cell Lymphoma (MCL) 5 2023-11-20
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Extensive stage small cell lung cancer (ES-SCLC). 5 2025-09-18